Mirapexin

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

pramipexole dihydrochloride monohydrate

Available from:

Boehringer Ingelheim International GmbH

ATC code:

N04BC05

INN (International Name):

pramipexole

Therapeutic group:

Mediċini Kontra l-Parkinson

Therapeutic area:

Restless Legs Syndrome; Parkinson Disease

Therapeutic indications:

Mirapexin huwa indikat għat-trattament tas-sinjali u sintomi tal-marda ta 'Parkinson idjopatika, waħedha (mingħajr levodopa) jew flimkien ma' levodopa, i. matul il-kors tal-marda, sa stadji tardivi meta l-effett ta 'levodopa jilbes jew isir inkonsistenti u jseħħu ċaqliq fl-effett terapewtiku (varjazzjonijiet fit-tmiem tad-doża jew' on-off '). Mirapexin hu indikat għall-kura sintomatika ta moderata għal severa idjopatika kwiet-sindrome tas-saqajn, f'dożaġġi sa 0. 54 mg ta ' bażi (0. 75 mg ta ' melħ).

Product summary:

Revision: 40

Authorization status:

Awtorizzat

Authorization date:

1998-02-23

Patient Information leaflet

                                68
B. FULJETT TA’ TAGĦRIF
69
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
MIRAPEXIN 0.088 MG PILLOLI
MIRAPEXIN 0.18 MG PILLOLI
MIRAPEXIN 0.35 MG PILLOLI
MIRAPEXIN 0.7 MG PILLOLI
pramipexole
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu MIRAPEXIN u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu MIRAPEXIN
3.
Kif għandek tieħu MIRAPEXIN
4.
Effetti sekondarji possibbli
5.
Kif taħżen MIRAPEXIN
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU MIRAPEXIN U GЋALXIEX JINTUŻA
MIRAPEXIN fih is-sustanza attiva pramipexole u jappartjeni għal grupp
ta’ prodotti mediċinali
magħrufa bħala agonisti ta’ dopamine, li jistimulaw ir-riċetturi
ta’ dopamine fil-moħħ. L-
istimulazzjoni tar-riċetturi ta’ dopamine tikkawża impulsi
tan-nervituri fil-moħħ li jgħinu biex
jikkontrollaw il-movimenti tal-ġisem.
MIRAPEXIN JINTUŻA BIEX:
-
jikkura s-sintomi tal-marda ta’ Parkinson primarja fl-adulti.
Jista’ jintuża waħdu jew flimkien ma’
levodopa (mediċina oħra għall-marda ta’ Parkinson).
-
jikkura s-sintomi tas-Sindrome tar-Riġlejn Irrekwieti (_Restless Legs
Syndrome_ - RLS) primarju fl-
adulti li jkun minn moderat sa sever.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU MIRAPEXIN
TIĦUX MIRAPEXIN
-
jekk inti allerġiku għal pramipexole jew għal xi sustanza oħra
ta’ din il-mediċina (imniżżla fis-
sezzjoni 6).
TWISSIJIET U PREKAWZJONIJIET
Kellem lit-tabib tiegħek qabel 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
MIRAPEXIN 0.088 mg pilloli
MIRAPEXIN 0.18 mg pilloli
MIRAPEXIN 0.35 mg pilloli
MIRAPEXIN 0.7 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
MIRAPEXIN 0.088 mg pilloli
Kull pillola fiha 0.125 mg ta’ pramipexole dihydrochloride
monohydrate ekwivalenti għal 0.088 mg
ta’ pramipexole.
MIRAPEXIN 0.18 mg pilloli
Kull pillola fiha 0.25 mg ta’ pramipexole dihydrochloride
monohydrate ekwivalenti għal 0.18 mg ta’
pramipexole.
MIRAPEXIN 0.35 mg pilloli
Kull pillola fiha 0.5 mg ta’ pramipexole dihydrochloride monohydrate
ekwivalenti għal 0.35 mg ta’
pramipexole.
MIRAPEXIN 0.7 mg pilloli
Kull pillola fiha 1.0 mg ta’ pramipexole dihydrochloride monohydrate
ekwivalenti għal 0.7 mg ta’
pramipexole.
_Jekk jogħġbok innota:_
Id-dożi ta’ pramipexole kif ippubblikati fil-letteratura jirreferu
għas-sura tal-melħ.
Għalhekk, id-dożi ser ikunu espressi f’termini kemm ta’ bażi
ta’ pramipexole kif ukoll ta’ melħ ta’
pramipexole (fil-parentesi).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola.
MIRAPEXIN 0.088 mg pilloli
Il-pilloli huma ta’ lewn abjad, ċatti, tondi, u għandhom kodiċi
bbuzzata (naħa minnhom bil-kodiċi P6,
u n-naħa l-oħra bis-simbolu tal-kumpanija Boehringer Ingelheim).
MIRAPEXIN 0.18 mg pilloli
Il-pilloli huma ta’ lewn abjad, ċatti, għandhom forma ovali,
b’sinjal imnaqqax fuq iż-żewġ naħat, u
għandhom kodiċi bbuzzata (naħa minnhom bil-kodiċi P7, u n-naħa
l-oħra bis-simbolu tal-kumpanija
Boehringer Ingelheim).
Il-pilloli jistgħu jinqasmu min-nofs f’dożi ndaqs.
MIRAPEXIN 0.35 mg pilloli
Il-pilloli huma ta’ lewn abjad, ċatti, għandhom forma ovali,
b’sinjal imnaqqax fuq iż-żewġ naħat, u
għandhom kodiċi bbuzzata (naħa minnhom bil-kodiċi P8, u n-naħa
l-oħra bis-simbolu tal-kumpanija
Boehringer Ingelheim).
Il-pilloli jistgħu jinqasmu min-nofs f’dożi ndaqs.
3
MIRAPEXIN 0.7 mg pilloli
Il-pilloli huma ta’ lewn abjad,
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-01-2024
Public Assessment Report Public Assessment Report Bulgarian 06-01-2011
Patient Information leaflet Patient Information leaflet Spanish 23-01-2024
Public Assessment Report Public Assessment Report Spanish 06-01-2011
Patient Information leaflet Patient Information leaflet Czech 23-01-2024
Public Assessment Report Public Assessment Report Czech 06-01-2011
Patient Information leaflet Patient Information leaflet Danish 23-01-2024
Public Assessment Report Public Assessment Report Danish 06-01-2011
Patient Information leaflet Patient Information leaflet German 23-01-2024
Public Assessment Report Public Assessment Report German 06-01-2011
Patient Information leaflet Patient Information leaflet Estonian 23-01-2024
Public Assessment Report Public Assessment Report Estonian 06-01-2011
Patient Information leaflet Patient Information leaflet Greek 23-01-2024
Public Assessment Report Public Assessment Report Greek 06-01-2011
Patient Information leaflet Patient Information leaflet English 23-01-2024
Public Assessment Report Public Assessment Report English 06-01-2011
Patient Information leaflet Patient Information leaflet French 23-01-2024
Public Assessment Report Public Assessment Report French 06-01-2011
Patient Information leaflet Patient Information leaflet Italian 23-01-2024
Public Assessment Report Public Assessment Report Italian 06-01-2011
Patient Information leaflet Patient Information leaflet Latvian 23-01-2024
Public Assessment Report Public Assessment Report Latvian 06-01-2011
Patient Information leaflet Patient Information leaflet Lithuanian 23-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-01-2024
Public Assessment Report Public Assessment Report Lithuanian 06-01-2011
Patient Information leaflet Patient Information leaflet Hungarian 23-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 23-01-2024
Public Assessment Report Public Assessment Report Hungarian 06-01-2011
Patient Information leaflet Patient Information leaflet Dutch 23-01-2024
Public Assessment Report Public Assessment Report Dutch 06-01-2011
Patient Information leaflet Patient Information leaflet Polish 23-01-2024
Public Assessment Report Public Assessment Report Polish 06-01-2011
Patient Information leaflet Patient Information leaflet Portuguese 23-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 23-01-2024
Public Assessment Report Public Assessment Report Portuguese 06-01-2011
Patient Information leaflet Patient Information leaflet Romanian 23-01-2024
Public Assessment Report Public Assessment Report Romanian 06-01-2011
Patient Information leaflet Patient Information leaflet Slovak 23-01-2024
Public Assessment Report Public Assessment Report Slovak 06-01-2011
Patient Information leaflet Patient Information leaflet Slovenian 23-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 23-01-2024
Public Assessment Report Public Assessment Report Slovenian 06-01-2011
Patient Information leaflet Patient Information leaflet Finnish 23-01-2024
Public Assessment Report Public Assessment Report Finnish 06-01-2011
Patient Information leaflet Patient Information leaflet Swedish 23-01-2024
Public Assessment Report Public Assessment Report Swedish 06-01-2011
Patient Information leaflet Patient Information leaflet Norwegian 23-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 23-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 23-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 23-01-2024
Patient Information leaflet Patient Information leaflet Croatian 23-01-2024

View documents history